necroptosis inhibitor - Ontology Report - Rat Genome Database

Submit Data | Help | Video Tutorials | News | Publications | Download | REST API | Citing RGD | Contact

CHEBI ONTOLOGY - ANNOTATIONS

{{ watchLinkText }}

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:	necroptosis inhibitor	go back to main search page
Accession:	CHEBI:167704	browse the term
Definition:	Any substance that inhibits the process of necroptosis (programmed form of necrosis) in organisms.
Synonyms:	related_synonym:	necroptosis inhibitors

show annotations for term's descendants Sort by:
Rat (34) Mouse (34) Human (34) Chinchilla (0) Bonobo (0) Dog (0) Squirrel (0) Pig (0) Green Monkey (0) Naked Mole-rat (0) All
Genes (34)

quizartinib

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

AKT serine/threonine kinase 1

multiple interactions
decreases phosphorylation

(+)-JQ1 compound promotes the reaction [quizartinib results in decreased phosphorylation of AKT1 protein]; quizartinib promotes the reaction [(+)-JQ1 compound results in decreased phosphorylation of AKT1 protein]

NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921

G

BCL2, apoptosis regulator

multiple interactions
decreases expression

(+)-JQ1 compound promotes the reaction [quizartinib results in decreased expression of BCL2 protein]; quizartinib promotes the reaction [(+)-JQ1 compound results in decreased expression of BCL2 protein]

NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743

G

Bcl2-like 11

multiple interactions
increases expression

(+)-JQ1 compound promotes the reaction [quizartinib results in increased expression of BCL2L11 protein]; quizartinib promotes the reaction [(+)-JQ1 compound results in increased expression of BCL2L11 protein]

NCBI chr 3:115,366,783...115,404,068
Ensembl chr 3:115,366,646...115,404,068

G

caspase 3

multiple interactions
increases cleavage

quizartinib affects the reaction [RGFP966 results in increased cleavage of CASP3 protein]; quizartinib promotes the reaction [romidepsin results in increased cleavage of CASP3 protein]; RGFP966 affects the reaction [quizartinib results in increased cleavage of CASP3 protein]; romidepsin promotes the reaction [quizartinib results in increased cleavage of CASP3 protein]

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

cyclin-dependent kinase 4

multiple interactions
decreases expression

(+)-JQ1 compound promotes the reaction [quizartinib results in decreased expression of CDK4 protein]; quizartinib promotes the reaction [(+)-JQ1 compound results in decreased expression of CDK4 protein]

NCBI chr 7:62,886,124...62,889,562
Ensembl chr 7:62,883,105...62,942,403

G

cyclin-dependent kinase 6

multiple interactions
decreases expression

(+)-JQ1 compound promotes the reaction [quizartinib results in decreased expression of CDK6 protein]; quizartinib promotes the reaction [(+)-JQ1 compound results in decreased expression of CDK6 protein]

NCBI chr 4:30,637,650...30,829,688
Ensembl chr 4:30,646,460...30,829,634

G

cyclin-dependent kinase inhibitor 1A

multiple interactions
increases expression
decreases expression

(+)-JQ1 compound promotes the reaction [quizartinib results in increased expression of CDKN1A protein]; quizartinib inhibits the reaction [RGFP966 results in increased expression of CDKN1A protein]; quizartinib inhibits the reaction [romidepsin results in increased expression of CDKN1A protein]; quizartinib promotes the reaction [(+)-JQ1 compound results in increased expression of CDKN1A protein]
quizartinib results in decreased expression of CDKN1A protein

PMID:25053825 PMID:34665271

NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585

G

checkpoint kinase 1

decreases expression
multiple interactions

quizartinib results in decreased expression of CHEK1 protein
quizartinib promotes the reaction [RGFP966 results in decreased expression of CHEK1 protein]; quizartinib results in decreased expression of and results in increased phosphorylation of CHEK1 protein; RGFP966 promotes the reaction [quizartinib results in decreased expression of CHEK1 protein]; romidepsin promotes the reaction [quizartinib results in decreased expression of and results in increased phosphorylation of CHEK1 protein]

NCBI chr 8:36,420,565...36,443,477
Ensembl chr 8:36,420,569...36,441,009

G

cathepsin A

multiple interactions

[quizartinib co-treated with spautin-1 co-treated with Chloroquine] results in increased transport of and affects the localization of CTSA protein

NCBI chr 3:153,569,106...153,574,983
Ensembl chr 3:153,568,381...153,576,215

G

cathepsin B

multiple interactions

[quizartinib co-treated with spautin-1 co-treated with Chloroquine] results in increased transport of and affects the localization of CTSB protein

NCBI chr15:37,389,636...37,410,508
Ensembl chr15:37,389,629...37,410,500

G

cathepsin D

multiple interactions

[quizartinib co-treated with spautin-1 co-treated with Chloroquine] results in increased transport of and affects the localization of CTSD protein

NCBI chr 1:197,527,467...197,539,343
Ensembl chr 1:197,527,467...197,539,488

G

DEAD-box helicase 3, X-linked

multiple interactions

[quizartinib co-treated with spautin-1 co-treated with Chloroquine] results in increased transport of and affects the localization of DDX3X protein; [quizartinib co-treated with spautin-1] results in increased degradation of DDX3X protein; aloxistatin inhibits the reaction [[quizartinib co-treated with spautin-1] results in increased degradation of DDX3X protein]; Chloroquine inhibits the reaction [[quizartinib co-treated with spautin-1] results in increased degradation of DDX3X protein]; LAMP2 protein alternative form affects the reaction [[quizartinib co-treated with spautin-1 co-treated with Chloroquine] results in increased transport of and affects the localization of DDX3X protein]; leupeptin inhibits the reaction [[quizartinib co-treated with spautin-1] results in increased degradation of DDX3X protein]

NCBI chr X:9,479,532...9,493,169
Ensembl chr X:9,479,532...9,493,168

G

eukaryotic translation initiation factor 4A1

multiple interactions

[quizartinib co-treated with spautin-1 co-treated with Chloroquine] results in increased transport of and affects the localization of EIF4A1 protein; [quizartinib co-treated with spautin-1] results in increased degradation of EIF4A1 protein; aloxistatin inhibits the reaction [[quizartinib co-treated with spautin-1] results in increased degradation of EIF4A1 protein]; Chloroquine inhibits the reaction [[quizartinib co-treated with spautin-1] results in increased degradation of EIF4A1 protein]; LAMP2 protein alternative form affects the reaction [[quizartinib co-treated with spautin-1 co-treated with Chloroquine] results in increased transport of and affects the localization of EIF4A1 protein]; leupeptin inhibits the reaction [[quizartinib co-treated with spautin-1] results in increased degradation of EIF4A1 protein]

NCBI chr10:54,384,345...54,389,855
Ensembl chr10:54,384,347...54,389,858

G

eukaryotic translation initiation factor 4H

multiple interactions

[quizartinib co-treated with spautin-1 co-treated with Chloroquine] results in increased transport of and affects the localization of EIF4H protein; [quizartinib co-treated with spautin-1] results in increased degradation of EIF4H protein; aloxistatin inhibits the reaction [[quizartinib co-treated with spautin-1] results in increased degradation of EIF4H protein]; Chloroquine inhibits the reaction [[quizartinib co-treated with spautin-1] results in increased degradation of EIF4H protein]; LAMP2 protein alternative form affects the reaction [[quizartinib co-treated with spautin-1 co-treated with Chloroquine] results in increased transport of and affects the localization of EIF4H protein]; leupeptin inhibits the reaction [[quizartinib co-treated with spautin-1] results in increased degradation of EIF4H protein]

NCBI chr12:22,083,155...22,099,876
Ensembl chr12:22,082,835...22,099,876

G

Fms related receptor tyrosine kinase 3

multiple interactions
decreases phosphorylation

quizartinib affects the reaction [RGFP966 results in decreased expression of and results in decreased phosphorylation of FLT3 protein alternative form]; quizartinib promotes the reaction [romidepsin results in decreased phosphorylation of FLT3 protein alternative form]; RGFP966 affects the reaction [quizartinib results in decreased phosphorylation of FLT3 protein alternative form]; romidepsin promotes the reaction [quizartinib results in decreased phosphorylation of FLT3 protein alternative form]

NCBI chr12:7,623,930...7,699,474
Ensembl chr12:7,623,930...7,699,474

G

H2A.X variant histone

multiple interactions
increases phosphorylation

quizartinib affects the reaction [RGFP966 results in increased phosphorylation of H2AX protein]; quizartinib promotes the reaction [romidepsin results in increased phosphorylation of H2AX protein]; RGFP966 affects the reaction [quizartinib results in increased phosphorylation of H2AX protein]; romidepsin promotes the reaction [quizartinib results in increased phosphorylation of H2AX protein]

NCBI chr 8:44,671,907...44,673,262
Ensembl chr 8:44,671,786...44,673,239

G

H3.4 histone, cluster member

multiple interactions

quizartinib promotes the reaction [romidepsin results in increased acetylation of H3-4 protein]

NCBI chr10:43,740,702...43,741,262

G

HEXIM P-TEFb complex subunit 1

multiple interactions

quizartinib inhibits the reaction [(+)-JQ1 compound results in increased expression of HEXIM1 protein]

NCBI chr10:88,062,808...88,064,920
Ensembl chr10:88,062,803...88,066,189

G

histone cluster 1, H4m

multiple interactions

quizartinib promotes the reaction [RGFP966 results in increased acetylation of H4C1 protein]

NCBI chr17:42,698,016...42,698,420
Ensembl chr17:42,698,025...42,698,958

G

hexokinase 2

multiple interactions

[quizartinib co-treated with spautin-1 co-treated with Chloroquine] results in increased transport of and affects the localization of HK2 protein; LAMP2 protein alternative form affects the reaction [[quizartinib co-treated with spautin-1 co-treated with Chloroquine] results in increased transport of and affects the localization of HK2 protein]

NCBI chr 4:115,234,509...115,283,530
Ensembl chr 4:115,234,509...115,283,530

G

heat shock protein family A (Hsp70) member 8

multiple interactions

[quizartinib co-treated with spautin-1 co-treated with Chloroquine] results in increased transport of and affects the localization of HSPA8 protein alternative form

NCBI chr 8:41,183,397...41,187,260
Ensembl chr 8:41,183,264...41,187,259

G

lysosomal-associated membrane protein 2

multiple interactions

[quizartinib co-treated with spautin-1 co-treated with Chloroquine] results in increased transport of and affects the localization of LAMP2 protein; [quizartinib co-treated with spautin-1 co-treated with Chloroquine] results in increased transport of and affects the localization of LAMP2 protein alternative form; LAMP2 protein alternative form affects the reaction [[quizartinib co-treated with spautin-1 co-treated with Chloroquine] results in increased transport of and affects the localization of DDX3X protein]; LAMP2 protein alternative form affects the reaction [[quizartinib co-treated with spautin-1 co-treated with Chloroquine] results in increased transport of and affects the localization of EIF4A1 protein]; LAMP2 protein alternative form affects the reaction [[quizartinib co-treated with spautin-1 co-treated with Chloroquine] results in increased transport of and affects the localization of EIF4H protein]; LAMP2 protein alternative form affects the reaction [[quizartinib co-treated with spautin-1 co-treated with Chloroquine] results in increased transport of and affects the localization of HK2 protein]; LAMP2 protein alternative form affects the reaction [[quizartinib co-treated with spautin-1 co-treated with Chloroquine] results in increased transport of and affects the localization of LAMP2 protein]; LAMP2 protein alternative form affects the reaction [[quizartinib co-treated with spautin-1 co-treated with Chloroquine] results in increased transport of and affects the localization of NFKBIA protein]

NCBI chr X:117,173,097...117,222,090
Ensembl chr X:117,057,606...117,260,522

G

mitogen activated protein kinase 1

multiple interactions
decreases phosphorylation

(+)-JQ1 compound promotes the reaction [quizartinib results in decreased phosphorylation of MAPK1 protein]; quizartinib affects the reaction [RGFP966 results in decreased phosphorylation of MAPK1 protein]; quizartinib promotes the reaction [(+)-JQ1 compound results in decreased phosphorylation of MAPK1 protein]; quizartinib promotes the reaction [romidepsin results in decreased phosphorylation of MAPK1 protein]; RGFP966 affects the reaction [quizartinib results in decreased phosphorylation of MAPK1 protein]; romidepsin promotes the reaction [quizartinib results in decreased phosphorylation of MAPK1 protein]

PMID:25053825 PMID:34665271

NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616

G

mitogen activated protein kinase 3

multiple interactions
decreases phosphorylation

(+)-JQ1 compound promotes the reaction [quizartinib results in decreased phosphorylation of MAPK3 protein]; quizartinib affects the reaction [RGFP966 results in decreased phosphorylation of MAPK3 protein]; quizartinib promotes the reaction [(+)-JQ1 compound results in decreased phosphorylation of MAPK3 protein]; quizartinib promotes the reaction [romidepsin results in decreased phosphorylation of MAPK3 protein]; RGFP966 affects the reaction [quizartinib results in decreased phosphorylation of MAPK3 protein]; romidepsin promotes the reaction [quizartinib results in decreased phosphorylation of MAPK3 protein]

PMID:25053825 PMID:34665271

NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863

G

MYC proto-oncogene, bHLH transcription factor

multiple interactions
decreases expression

(+)-JQ1 compound promotes the reaction [quizartinib results in decreased expression of MYC protein]; quizartinib promotes the reaction [(+)-JQ1 compound results in decreased expression of MYC protein]

NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630

G

NFKB inhibitor alpha

multiple interactions

[quizartinib co-treated with spautin-1 co-treated with Chloroquine] results in increased transport of and affects the localization of NFKBIA protein; LAMP2 protein alternative form affects the reaction [[quizartinib co-treated with spautin-1 co-treated with Chloroquine] results in increased transport of and affects the localization of NFKBIA protein]

NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941

G

poly (ADP-ribose) polymerase 1

multiple interactions
increases cleavage

(+)-JQ1 compound promotes the reaction [quizartinib results in increased cleavage of PARP1 protein]; quizartinib promotes the reaction [(+)-JQ1 compound results in increased cleavage of PARP1 protein]

NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404

G

RAD51 recombinase

decreases expression
multiple interactions

quizartinib results in decreased expression of RAD51 protein
quizartinib promotes the reaction [romidepsin results in decreased expression of RAD51 protein]; romidepsin promotes the reaction [quizartinib results in decreased expression of RAD51 protein]

NCBI chr 3:106,099,753...106,125,038
Ensembl chr 3:106,100,381...106,125,035

G

replication protein A2

multiple interactions
increases phosphorylation

quizartinib affects the reaction [RGFP966 results in increased phosphorylation of RPA2 protein]; RGFP966 affects the reaction [quizartinib results in increased phosphorylation of RPA2 protein]

NCBI chr 5:144,976,789...144,989,445
Ensembl chr 5:144,976,748...144,987,350

G

signal transducer and activator of transcription 5A

multiple interactions
decreases phosphorylation

(+)-JQ1 compound promotes the reaction [quizartinib results in decreased phosphorylation of STAT5A protein]; quizartinib promotes the reaction [(+)-JQ1 compound results in decreased phosphorylation of STAT5A protein]

NCBI chr10:85,785,537...85,809,869
Ensembl chr10:85,785,537...85,809,866

G

signal transducer and activator of transcription 5B

multiple interactions
decreases phosphorylation

(+)-JQ1 compound promotes the reaction [quizartinib results in decreased phosphorylation of STAT5B protein]; quizartinib promotes the reaction [(+)-JQ1 compound results in decreased phosphorylation of STAT5B protein]

NCBI chr10:85,704,841...85,775,856
Ensembl chr10:85,705,670...85,775,668

G

tumor protein p53

decreases expression
multiple interactions

quizartinib results in decreased expression of TP53 protein
RGFP966 promotes the reaction [quizartinib results in decreased expression of TP53 protein]; romidepsin promotes the reaction [quizartinib results in decreased expression of TP53 protein]

NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524

G

thymidylate synthetase

decreases expression

quizartinib results in decreased expression of TYMS protein

NCBI chr 9:113,313,454...113,329,551
Ensembl chr 9:113,313,452...113,329,536

G

WEE1 G2 checkpoint kinase

multiple interactions
decreases expression

quizartinib promotes the reaction [RGFP966 results in decreased expression of WEE1 protein]; quizartinib promotes the reaction [romidepsin results in decreased expression of WEE1 protein]; RGFP966 promotes the reaction [quizartinib results in decreased expression of WEE1 protein]; romidepsin promotes the reaction [quizartinib results in decreased expression of WEE1 protein]

NCBI chr 1:164,173,681...164,197,688
Ensembl chr 1:164,174,779...164,197,688

Term paths to the root

Path 1
Term	Annotations
CHEBI ontology	19808
role	19784
biological role	19782
biochemical role	19496
necroptosis inhibitor	34
LY3009120	0
TAK-632	0
necrosulfonamide	0
quizartinib	34

paths to the root